Nurix Therapeutics Inc.

NRIX

Held by 11 specialist biotech funds

High ConvergenceHigh short interest · No specialist buying

11 funds opened new positions. Next phase2 readout (NX-5948): Jan 2028. Short interest: 17.5% of float.

Recent News & Research

bioRxiv

Bexobrutideg: A Selective, Catalytic Degrader of Bruton's Tyrosine Kinase Overcomes Inhibitor Resistance and Suppresses Autoantibody-Mediated Disease

# Investment Summary: Nurix Bexobrutinib (BTK Degrader) Bexobrutinib demonstrates superior activity to BTK inhibitors by achieving complete BTK degradation rather than reversible inhibition, potentially overcoming clinical resistance mechanisms observed in BTK inhibitor-treated patients with B-cell malignancies and autoimmune diseases. The mechanism's ability to suppress autoantibody production suggests competitive advantages in autoimmune indications (e.g., lupus, rheumatoid arthritis) where current BTK inhibitors show limited efficacy, potentially expanding addressable markets beyond oncology. If Phase 2/3 data confirm this preclinical superiority in resistant patient populations, bexobrutinib could capture market share from established BTK inhibitors, though regulatory pathway clarity and head-to-head efficacy comparisons remain critical to commercial success. **Key Investor Consideration:** The

Aug 4, 2026

PubMed

Selective degradation of platelet BTK by PROTAC NX-5948 provides antithrombotic benefits without affecting haemostasis.

# Nurix Therapeutics (NRIX) - NX-5948 Research Summary **Investment Significance:** NX-5948, Nurix's BTK PROTAC degrader, demonstrates selective platelet BTK degradation that achieves antithrombotic efficacy while preserving hemostatic function—a critical safety advantage over irreversible BTK inhibitors like ibrutinib that cause bleeding complications. This selectivity could expand the addressable market beyond current BTK inhibitor use cases by enabling safer deployment in thrombotic conditions (e.g., cardiovascular disease, stroke prevention) where bleeding risk currently limits treatment options. The differentiated mechanism positions NX-5948 for potential competitive advantage if clinical data continues supporting improved tolerability, though clinical-stage progression and comparative efficacy data remain key variables for valuation impact.

Jun 30, 2026

Nurix Therapeutics Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Activist Filings

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research